Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2781-2790 Newer>

AFP eWire March 27, 2006	Grassley to Investigate Nonprofit Hospitals The chair of the Senate Finance Committee and the lead critic of nonprofits in Congress, is now expanding his investigation of the sector into nonprofit hospitals.
The Motley Fool March 27, 2006 Rich Smith	Bayer Prescribes Itself a Buyout Bayer's bid for Schering trumped an earlier $17.5 billion offer from yet another German powerhouse, Merck KGaA. Why would Bayer pay so much for Schering? Investors, take note.
BusinessWeek April 3, 2006 Michael Arndt	An Alternative For Cancer Patients For-profit treatment centers are competing with community and teaching hospitals.
The Motley Fool March 24, 2006 Brian Gorman	Cephalon Takes a Hit The FDA rules against its ADHD drug, but Cephalon's current lineup still holds promise. Investors may want to look at the current sell-off as a potential buying opportunity.
BusinessWeek April 3, 2006 Gene G. Marcial	Andrx: Many Hurdles Before The Deal Is Done Generic-drug maker Andrx agreed to be acquired by Watson Pharmaceuticals. But MMI Investments, the biggest stakeholder, with 12.3%, plans to oppose the deal, which is still awaiting regulatory approval, and others could follow suit.
The Motley Fool March 20, 2006 Brian Gorman	Much Ado About PAREXEL The contract research services provider's shares have been on a roller coaster ride lately, but the ups and downs don't make a lot of sense. Investors, take note.
The Motley Fool March 20, 2006 Rich Duprey	ViroPharma's Generic Discount This tiny biotech looks cheap in light of sell-off over generics threat. Investors would do well to look a little closer at this promising biotech.
The Motley Fool March 17, 2006 Rich Duprey	Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note.
BusinessWeek March 27, 2006 Steve Hamm	The Mayo Clinic's Best Devices Thanks to innovative partnerships, the Mayo CLinic is able to develop and market medical gear under its own name - and in record time.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
<Older 2781-2790 Newer> Return to current articles.